Loading...
Breast Cancer Immunotherapy: Facts and Hopes
Immunotherapy is revolutionizing the management of multiple solid tumors, and early data have revealed the clinical activity of PD-1/PD-L1 antagonists in small numbers of metastatic breast cancer patients. Clinical activity appears more likely if the tumor is triple negative, PD-L1+, and/or harbors...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5796849/ https://ncbi.nlm.nih.gov/pubmed/28801472 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-3001 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|